FDA Authorizes New Immunotherapy for Stage III dMMR Colon Cancer

The U.S. Food and Drug Administration (FDA) has approved Tecentriq and Tecentriq Hybreza, combined with chemotherapy, for adjuvant treatment of stage III dMMR colon cancer. This marks the first immunotherapy-based adjuvant option for this patient group, following a Phase III trial showing a 50% reduction in disease recurrence or death. This approval offers a new treatment pathway for patients with this specific cancer type.